New Targets and Innovative Strategies in Cancer Treatment: A Short Course for Clinicians

Last Modified: November 17, 2002

Share article


Conference Dates: February 6-8, 2003
Conference Location: Monte Carlo, Monaco


Sponsoring Group: Imedex, Inc.

Conference Web Page URL: www.imedex.com/calendars/oncology.htm

Topics Covered: The course has been designed with three specific objectives in mind. The first objective is to explain, and to clarify in an often somewhat simplified way the mechanisms of cell growth and multiplication. The program will cover the role of extracellular growth factors and growth factor receptors, the intracellular signal transduction to the nucleus, the selective activation and transcription of genes, the translation into proteins, the events that initiate DNA replication, or push a cell towards apoptosis. The second objective is to illustrate which aspects of these mechanisms constitute attractive new targets for cancer therapy, which products have become available or are in development, how they interfere with the various mechanisms in cancer cells, and what results have been obtained (preclinically or clinically, if available) with each of these approaches thus far. Antibodies against growth factors and their receptors, tyrosine kinase and farne! syl transferase inhibitors, apoptosis induces, proteasome inhibitors, antiangiogenesis and antisense products are featured on the program.Because of their nature, and more specifically their mechanisms of action, many of these products are not suitable for the traditional clinical development approach in oncology. Some may work only in conjunction with others. Clinicians will have to learn and adapt to new trial designs in terms of endpoints, selection criteria, complex combinations, and schedules. The meeting will conclude with a brief discussion of the key issues in the clinical development of these agents.

Conference Objectives: After successful completion of this course, participants should have a clear picture of the basic mechanisms of cell growth, multiplication, apoptosis and differentiation and how these may be disturbed in cancer cells. They should be able to position and evaluate the relevance of research papers on these topics, be aware of the developmental stages of these targeted therapies, and have a feel for the likelihood and the speed with which they may become of interest in clinical practice. They should also have a good grasp of the implications of these products, and their mechanisms of action, on clinical trial design and interpretation.

Who Should Attend: The course has been designed specifically for practicing oncologists whose busy practices make it difficult to keep up with the clinical literature, let alone to keep track of the vast amount of data that have unraveled much of the basic biology of cell growth and multiplication over the past ten years. Every effort has been done to select faculty who are not only very knowledgeable in their respective areas of expertise, but who also have the profound basic understanding and the didactic ability to communicate it clearly and concisely to an audience with much less expertise. This course is not designed for superspecialized experts in their respective fields. This meeting is not a meeting where experts talk to other experts. Nevertheless, some experts in one aspect of cell biology may wish to acquire a more global picture and familiarize themselves with aspects of cellular and cancer biology which is somewhat beyond their own scope.

Registration Information: Four EASY ways to register:

  1. Online... Register online at www.imedex.com
  2. Call us... The Registrar will take your registration over the phone. +1 (770) 751 7332
  3. Fax us... If paying by credit card, you can fax your registration. +1 (770) 751 7334
  4. Mail us... Imedex7 70 Technology Drive Alpharetta, GA 30005-3969 USA

Conference Fees: EUR 349 if registered by January 3, 2003. EUR 449 if registered by January 31, 2003, EUR 549 after January 31st. Discount for ESMO members.

Continuing Education: Yes

Miscellany: ESMO certified


News
Either 2.5 or 3.75 percent short-course regimen can be used to treat actinic keratoses

Apr 6, 2010 - In patients with actinic keratoses, a short-course regimen of imiquimod 2.5 or 3.75 percent may be an effective treatment for the balding scalp or full face, according to research published in the April issue of the Journal of the American Academy of Dermatology.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More